1 Δεκ 2012 (πριν από 5 χρόνια και 6 μήνες)

330 εμφανίσεις


Issued 9 December, 2002
Release at 3 PM CET

Graffinity Pharmaceuticals AG
Helmut Kessmann, Ph.D.
Im Neuenheimer Feld 518 – 519
69120 Heidelberg, Germany

Phone +49 (0) 172 765 3251

In the U.S. Contact
Pete Holmberg
Rx Communications Group, LLC

Phone +1 917-322-2164


Dr Klaus Schollmeier to Lead Company as it evolves into a Drug Discovery and
Development Company

HEIDELBERG, Germany- December 4, 2002 - Graffinity Pharmaceuticals AG
(„Graffinity“) announced today that its Supervisory Board has appointed Klaus
Schollmeier, Ph.D., as Chief Executive Officer, effective January 1, 2003. Dr.
Schollmeier most recently served as Managing Director of the Healthcare/Biotechnology
Group at ING-BHF Bank for ING Group Europe („ING“) and previously held senior
management positions at BASF Pharma.

Commenting on Dr Schollmeier’s appointment Dr Michael Rheinnecker, Chairman
of the Supervisory Board said: "With the development of our technology platform now
complete and our lead discovery programs showing strong promise, our foremost goal
was to select an experienced CEO who could support Graffinity's evolution into a drug
discovery and development company. With Dr. Schollmeier, we have succeeded in
attracting someone who has a proven track record in developing such a company. His
in-depth knowledge of the pharmaceutical and biotechnology industries, as well as his
strong commercial and operational experience will greatly assist in the exploitation of
Graffinity’s unique technology base."

Dr. Schollmeier holds a Ph.D. in Biology from the University of Duesseldorf and in 1991
was appointed adjunct research Associate Professor at Boston University Medical
School. Prior to ING, Dr. Schollmeier, 45, spent 16 years at the Pharmaceutical division

of BASF, where he held a wide range of scientific and commercial responsibilities,
including Senior Director of Biotechnology at BASF Bioresearch Corporation in
Cambridge, MA, USA. From 1994 to 1995, he led BASF`s acquisition and integration of
Boots Pharmaceuticals. He became General Manager of BASF Pharma Netherlands in
1996 and was promoted to Vice President and General Manager for Western Europe in

Commenting on his appointment Dr. Schollmeier said: “ Over the last twenty years I
have had the opportunity to evaluate a large number of biotechnology companies world
wide and I believe Graffinity is one of the most exciting companies around. I have been
especially impressed by Graffinity’s technology offering and its ability to enter into a
large number of collaborations with world leading Pharmaceutical companies. I consider
Graffinity one of the most promising companies in the field of chemical genomics and am
convinced of its ability to generate novel small molecule therapeutics of worth for itself
and its partners. I am looking forward to demonstrate further the power of Graffinity's
RAISE (Rapid Affinity Informed Structure Evolution) approach and anticipate further
collaborations as well as taking our own preclinical programs forward over the next

Dr Schollmeier’s appointment complements the strong team now in place at Graffinity,
the most notable recent addition being Dr Victor Matassa who joined in January 2002 as
Head of Research and Development from Eli Lilly.

As Graffinity moves toward commercializing its technology Dr. Dirk Vetter, Co-founder
and former CEO, is leaving the company in mutual agreement to start up Complex
Biosystems, a new drug delivery venture based in Heidelberg, Germany.

Commenting on Dr. Vetter´s departure Dr. Rheinnecker said: "We are very grateful
to Dirk who led the development of Graffinity over a period of five years from conception
and foundation through three financing rounds. Dirk has done a tremendous job of
building the technology from scratch to a fully functional platform. It is due to his vision
and energy that Graffinity could reach such a promising position in the international
biotech industry. All of us at Graffinity wish Dirk every success for his next endeavor."

# # #

Graffinity Pharmaceuticals is a drug discovery and development company and leader
in the emerging field of chemical genomics. With its chemical microarray drug discovery
platform now fully operational; the establishment of corporate partnering programs; and
the initiation of internal development efforts, Graffinity is now ready to enter the next
stage of corporate development. Utilizing its technology base, Graffinity will continue to
pursue a small number of high-profile collaborations as well as building a pipeline of pre-
clinical product candidates.

Graffinity’s proprietary chemical genomics platform combines new chemistry
approaches, physics, information technology and microsystem technologies to screen
potential drug targets for its own pipeline as well as for leading biotechnology and
pharmaceutical partners worldwide. Critically important is the combination of chemical
microarrays with a proprietary method for the standardized, label-free detection of
compound-protein interactions. No assay development is necessary. Through Graffinity's

RAISE (Rapid Affinity Informed Structure Evolution) approach, small organic molecules
identified in the first round are quickly progressed into highly specific lead-like structures.
The result is rapid, scalable drug discovery, which explores a rich chemical universe to
find the compounds that will be needed to develop drugs against the wealth of targets
already available or those uncovered by genomics. The resulting lead structures are
licensed to its partners or further developed by its rapidly expanding medicinal chemistry

Graffinity has recently established collaborations with pharmaceutical and
biotechnological partners, including Pfizer, Aventis Pharma, and Eli Lilly. The Company,
based in Heidelberg, Germany, was founded in late 1997 and currently employs
approximately 90 people.

For more information, please visit

# # #

Notes for Editors

TechnoStart, founded in 1991, is an independent venture capital company specialised in
seed and early stage companies and has more than Euro 80 million under management.
The company has a proven track record as lead investor in enabling technologies in the
nanotechnology, life sciences and new materials sector.
Current investments span seven biotechnology companies: Cenix GmbH, Complex
Biosystems GmbH, Febit AG, Graffinity AG, IDEA AG, m-phasys GmbH and Spinox Ltd.